Samsung Biologics– tag –
-
Biologics CDMO Market Competitive Landscape Report: Lonza, Samsung Biologics, and WuXi Biologics Drive Growth
National Law Review USA Overview This article summarizes a report on the competitive landscape and growth drivers of the biologics CDMO market. Key players include Lonza Group Ltd, Samsung Biologics Co Ltd, WuXi Biologics Cayman Inc, The... -
Lonza, Samsung Biologics, and Catalent Lead 2026 Biologics CDMO Market, Driven by AI Manufacturing & APAC Expansion
Towards Healthcare Unknown Overview Lonza, Samsung Biologics, and Catalent are identified as key players leading the 2026 biologics CDMO market. Lonza excels in end-to-end multi-modality and scientific innovation, Samsung Biologics in la... -
Samsung Biologics Secures Multi-Year mRNA Vaccine CDMO Partnership with Major Pharma, Leading Market Expansion
Business Korea South Korea Overview Samsung Biologics has reportedly secured a multi-year contract for large-scale mRNA vaccine manufacturing with a global pharmaceutical company. This new partnership further solidifies Samsung Biologics... -
Top 20 Biomanufacturing and CDMO Providers for 2026: Driving Innovation in Biopharma Production
Healthcare Ranking USA Overview The 2026 ranking of top biomanufacturing and Contract Development and Manufacturing Organization (CDMO) providers highlights industry leaders such as Lonza, Samsung Biologics, WuXi Biologics, and Thermo Fi... -
Samsung Biologics Labor Dispute Stalls Wage Talks, Raising Concerns for Global CDMO Competitiveness
The Elec Inc. South Korea Overview Wage negotiations between management and labor union at Samsung Biologics have reached a prolonged stalemate, raising concerns about the company's global competitiveness in the Contract Development and ... -
Pharmaceutical Membrane Filtration Market: Size, Share, and Growth Forecast to 2034 – A Straits Research Overview
Straits Research Germany Overview This article provides an overview of a market research report published by Straits Research, detailing the pharmaceutical membrane filtration market's current status and projected growth to 2034. The rep... -
South Korean Biotech Giants Diverge: Samsung Biologics Faces Labor Risks Amid Record Growth, Celltrion Boosts Global CDMO Expansion
aju press South Korea Overview South Korea's leading biotech firms, Samsung Biologics and Celltrion, show divergent paths: Samsung Biologics achieved record Q1 2026 performance with 25.8% revenue growth due to full plant utilization but ... -
Pharmaceutical Manufacturing Realignments Create Expansion Opportunities for CDMOs: GSK, BMS, Sanofi Divest Facilities
Pharmaceutical Technology USA Overview A significant reconfiguration is underway in the pharmaceutical manufacturing sector, with major CDMOs acquiring production facilities from pharmaceutical companies. Samsung Biologics, Rois, and Adr...
